Safety was consistent across dosing groups, with no new safety signals observed and neutropenia well-managed. The majority of patients across both dose cohorts received prior bevacizumab. The ...

The late-breaking oral presentation at SGO 2025 highlights consistent response rates observed in patients across all levels of FRα expression of 25% or greater -SOUTH SAN FRANCISCO, Calif., March 15, ...

Drs Ursula A. Matulonis and Katherine Fuh discuss the molecular classification and genetics of endometrial cancer as well as when to rebiopsy, research updates, and what's to come in the future.